BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 19826047)

  • 41. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Han X; Medeiros LJ; Zhang YH; You MJ; Andreeff M; Konopleva M; Bueso-Ramos CE
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S30-8. PubMed ID: 27155969
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of distinctive long noncoding RNA competitive interactions and a six-methylated-gene prognostic signature in acute myeloid leukemia with -5/del(5q) or -7/del(7q).
    Yin X; Huang S; Xu A; Fan F; Chen L; Sun C; Hu Y
    J Cell Biochem; 2020 Feb; 121(2):1563-1574. PubMed ID: 31535409
    [TBL] [Abstract][Full Text] [Related]  

  • 43. GTPase regulator associated with the focal adhesion kinase (GRAF) transcript was down-regulated in patients with myeloid malignancies.
    Qian Z; Qian J; Lin J; Yao DM; Chen Q; Ji RB; Li Y; Xiao GF; Li JY
    J Exp Clin Cancer Res; 2010 Aug; 29(1):111. PubMed ID: 20704716
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New complex t(2;11;17)(p21;q23;q11), a variant form of t(2;11), associated with del(5)(q23q32) in myelodysplastic syndrome-derived acute myeloblastic leukemia.
    Yamamoto K; Nagata K; Morita Y; Inagaki K; Hamaguchi H
    Cancer Genet Cytogenet; 2002 Sep; 137(2):119-23. PubMed ID: 12393282
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q).
    Hecht A; Meyer JA; Jann JC; Sockel K; Giagounidis A; Götze KS; Letsch A; Haase D; Schlenk RF; Haferlach T; Schafhausen P; Bug G; Lübbert M; Thol F; Büsche G; Schuler E; Nowak V; Obländer J; Fey S; Müller N; Metzgeroth G; Hofmann WK; Germing U; Nolte F; Reinwald M; Nowak D
    Ann Hematol; 2021 Jun; 100(6):1463-1471. PubMed ID: 33903952
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
    Larsson CA; Cote G; Quintás-Cardama A
    Mol Cancer Res; 2013 Aug; 11(8):815-27. PubMed ID: 23645565
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rare tetraploidy with large 5q deletion in acute myeloid leukemia with myelodysplasia-related changes (AML-MRC).
    Jarosova M; Nedomova R; Hubacek J; Holzerova M; Mickova P; Katrincsakova B; Pikalova Z; Papajik T; Indrak K
    Leuk Res; 2012 Apr; 36(4):e68-70. PubMed ID: 22284693
    [No Abstract]   [Full Text] [Related]  

  • 48. Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5q.
    Treppendahl MB; Möllgård L; Hellström-Lindberg E; Cloos P; Grønbaek K
    Eur J Haematol; 2013 Mar; 90(3):259-60. PubMed ID: 23190153
    [No Abstract]   [Full Text] [Related]  

  • 49. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
    Rollison DE; Shain KH; Lee JH; Hampras SS; Fulp W; Fisher K; Al Ali NH; Padron E; Lancet J; Xu Q; Olesnyckyj M; Kenvin L; Knight R; Dalton W; List A; Komrokji RS
    Cancer Med; 2016 Jul; 5(7):1694-701. PubMed ID: 27098006
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia.
    Cechova H; Lassuthova P; Novakova L; Belickova M; Stemberkova R; Jencik J; Stankova M; Hrabakova P; Pegova K; Zizkova H; Cermak J
    Neoplasma; 2012; 59(2):168-74. PubMed ID: 22248274
    [TBL] [Abstract][Full Text] [Related]  

  • 51. β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q).
    Li L; Sheng Y; Li W; Hu C; Mittal N; Tohyama K; Seba A; Zhao YY; Ozer H; Zhu T; Qian Z
    Cancer Res; 2017 Aug; 77(15):4116-4126. PubMed ID: 28611040
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery of epigenetically silenced genes in acute myeloid leukemias.
    Desmond JC; Raynaud S; Tung E; Hofmann WK; Haferlach T; Koeffler HP
    Leukemia; 2007 May; 21(5):1026-34. PubMed ID: 17330099
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of chromosome 5 aberrations in complex karyotypes of patients with myeloid disorders reveals their contribution to dicentric and tricentric chromosomes, resulting in the loss of critical 5q regions.
    Herry A; Douet-Guilbert N; Morel F; Le Bris MJ; Morice P; Abgrall JF; Berthou C; De Braekeleer M
    Cancer Genet Cytogenet; 2007 Jun; 175(2):125-31. PubMed ID: 17556068
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups.
    Gadji M; Adebayo Awe J; Rodrigues P; Kumar R; Houston DS; Klewes L; Dièye TN; Rego EM; Passetto RF; de Oliveira FM; Mai S
    Clin Cancer Res; 2012 Jun; 18(12):3293-304. PubMed ID: 22539801
    [TBL] [Abstract][Full Text] [Related]  

  • 55. LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome.
    Kaastrup K; Gillberg L; Mikkelsen SU; Ørskov AD; Schöllkopf C; Mortensen BK; Porse B; Hansen JW; Grønbæk K
    Clin Epigenetics; 2023 May; 15(1):91. PubMed ID: 37237325
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
    Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O
    Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710
    [TBL] [Abstract][Full Text] [Related]  

  • 57. GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome.
    Zhou JD; Lin J; Zhang TJ; Ma JC; Yang L; Wen XM; Guo H; Yang J; Deng ZQ; Qian J
    Cancer Med; 2017 Jan; 6(1):267-274. PubMed ID: 27891827
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Chaudhary AK; Chaudhary S; Ghosh K; Shanmukaiah C; Nadkarni AH
    Asian Pac J Cancer Prev; 2016; 17(3):1519-29. PubMed ID: 27039800
    [TBL] [Abstract][Full Text] [Related]  

  • 59. dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53.
    Wang P; Spielberger RT; Thangavelu M; Zhao N; Davis EM; Iannantuoni K; Larson RA; Le Beau MM
    Genes Chromosomes Cancer; 1997 Nov; 20(3):282-91. PubMed ID: 9365836
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.
    Venugopal S; Mascarenhas J; Steensma DP
    Blood Rev; 2021 Mar; 46():100735. PubMed ID: 32736878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.